Beam Therapeutics

The Beam NC Team is focused, committed and proud to be part of a team that is dedicated to driving forward our vision of providing lifelong cures to patients suffering from serious diseases #DaretoBeamNC #BeamTeam 

Our Chief Technology Officer Manmohan Singh, PhD, FAAPS, will be taking the stage as a panelist during the plenary keynote at this year's Bioprocessing Summit on August 21. He’ll join other industry leaders in a fireside chat to discuss the transformative potential of genetic medicines, including the technologies, tools and strategies to succeed in the clinic and commercially. Learn more about the conference here: https://lnkd.in/eqYsS33 #CHIBioprocessingSummit 

Today, Beam reported second quarter 2024 financial results and provided updates across the company’s hematology and genetic disease franchises. Read the full press release here: https://lnkd.in/evwbtsJm #DaretoBeam #BeamTeam

This week we hosted an internal Speed Networking event in Cambridge and North Carolina with over 100 members of the Beam Team participating! The event aimed to: - Promote our mentorship program and value of hearing and sharing career stories. - Facilitate connections across Beam. - Practice talking about development.    Thanks to all of the #BeamTeam members who participated! #DaretoBeam

Last week, the #BeamTeam hosted PhD and Postdoc students from the University of Chicago’s MyChoice Program. The group had a chance to visit 10+ companies in the Boston area and while at Beam, they toured our Cambridge office, learned about the Beam story, and networked with members of the Beam Team! #DaretoBeam

Today, Beam announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. Read the full press release here: https://lnkd.in/eS_xr8uJ

The #BeamTeam's Luis Brito, Vice President, LNP Platform, will be co-leading a workshop at the Controlled Release Society meeting on July 8th. Learn more about the Therapeutic Genome Editing Workshop: Tools, Delivery Systems, Prospects and Challenges here: https://lnkd.in/dTFxydBe

Last week, our North Carolina team celebrated #Pride with a tie-dye event and attended the OUT! Raleigh Pride! #DaretoBeam

Today, Beam announced the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designed to precisely correct the underlying cause of severe alpha-1 antitrypsin deficiency (AATD), that is currently being evaluated in a Phase 1/2 clinical trial. Read the full press release here: https://lnkd.in/eUHQf7Bs #DaretoBeam #BeamTeam

Join Jenny Olins and Ajit Kamath, PhD on the Beam Analytical Research and Development Team! #DaretoBeam #BeamTeam https://lnkd.in/eEzUpH-A